Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.
The decrease came as improved performance by its biopharma services operations was more than offset by declines in clinical and discovery services revenues.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
The deal covers Cancer Genetics' microarray-based Tissue of Origin test, which analyzes 2,000 individual tumor genes to help identify a tumor's origin.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
